Post by Bristol Myers Squibb on X
Bristol Myers Squibb@bmsnews
X#MEDIA: Announcing the @US_FDA has granted priority review of the application for our #immunotherapy-based combination for adult and pediatric patients with previously untreated Stage III or IV Classical #HodgkinLymphoma. t.co

24 likes7 repliesPosted Dec 11, 2025